… The spike (S) protein of SARS-CoV-2 is the primary target of neutralizing antibodies (NAbs)
(Fig 1A). Therefore, NAbs against SARS-CoV-2 that have either been deployed for therapy …

… of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ab drugs for use
as COVID-19 therapeutic agents. The detailed structure of the SARS-CoV-2 spike protein is …

… Many randomised clinical trials of mAb therapy and prophylaxis have been launched, initially
… against SARS-CoV-2 (panel 1) to identify the strengths and weaknesses of this therapeutic …

… of newly emerging SARS-CoV-2 variants, we suggest the importance of rapid evaluation
of the efficiency of therapeutic monoclonal antibodies against novel SARS-CoV-2 variants. …

… of diagnostic and therapeutic monoclonal antibodies is the … grams of therapeutic monoclonal
antibodies annually but … production of diagnostic or therapeutic antibodies. Invivo and invitro …

… domain, the target of all authorized monoclonal antibodies (MAbs). … Monoclonal antibodies
(MAbs) targeting the SARS-CoV-2 … However, SARS-CoV-2 Omicron variants contain many …

… syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy
… In this study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (…

… for SARS-CoV-2 infection, with a focus on the therapeutic application of neutralizing antibodies
… Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathog. …

… human monoclonal antibody, HB27, that blocks SARS-CoV-2 … SARS-CoV-2 membrane
fusion. Consequently, a single dose of HB27 conferred effective protection against SARS-CoV-2 …

… authorized anti-Spike monoclonal antibodies (mAbs). … The heterogenous therapeutic
management of those cases … of mAb therapies and a subsequent increase in SARS-CoV-2 …